Nicholas Hollmeyer Lynton - 01 Jul 2023 Form 4 Insider Report for Cardlytics, Inc. (CDLX)

Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
CDLX
Transactions as of
01 Jul 2023
Net transactions value
-$60,684
Form type
4
Filing time
05 Jul 2023, 19:48:34 UTC
Previous filing
20 Apr 2023
Next filing
09 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDLX Common Stock Options Exercise $0 +25,000 +124% $0.000000 45,122 01 Jul 2023 Direct F1
transaction CDLX Common Stock Options Exercise $0 +581 +1.3% $0.000000 45,703 01 Jul 2023 Direct F1
transaction CDLX Common Stock Options Exercise $0 +6,311 +14% $0.000000 52,014 01 Jul 2023 Direct F1
transaction CDLX Common Stock Sale $60,684 -9,906 -19% $6.13 42,108 03 Jul 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDLX Restricted Stock Unit Options Exercise $0 -25,000 -25% $0.000000 75,000 01 Jul 2023 Common Stock 25,000 Direct F4, F5
transaction CDLX Restricted Stock Unit Options Exercise $0 -581 -8.3% $0.000000 6,394 01 Jul 2023 Common Stock 581 Direct F4, F6, F7, F8
transaction CDLX Restricted Stock Unit Options Exercise $0 -6,311 -25% $0.000000 18,936 01 Jul 2023 Common Stock 6,311 Direct F7, F8, F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the underlying vested shares of common stock of the Issuer which have not been delivered.
F2 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units ("RSUs") that vested on July 1, 2023.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.98 to $6.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon receipt, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Each RSU represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.
F5 25% of the RSUs shall vest on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2024, respectively, subject to the Reporting Person's continuous service with the Issuer through each applicable vesting date.
F6 Twenty-five percent (25%) of the shares under this award vest on April 1, 2023, with the remaining 75% vesting quarterly over the subsequent three years in equal amounts thereafter provided the Reporting Person continuously provides service to the Issuer through the vesting date.
F7 This number of RSUs granted was previously incorrectly reported this represents the correct number of RSUs remaining.
F8 This grant was previously incorrectly reported as a performance stock unit.
F9 Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F10 Twenty-five percent (25%) of the shares under this award vest on July 1, 2023, with the remaining 75% vesting quarterly over the subsequent three years in equal amounts thereafter provided the Reporting Person continuously provides service to the Issuer through the vesting date.